• About Us
    • Overview
    • Management
    • Board of Directors
    • Contact Us
  • Products
    • Overview
    • LibiGel®
    • Elestrin™
    • The Pill-Plus™
    • Testosterone Gel For Men
  • Partners & Licenses
    • Overview
    • Opportunities
  • Therapeutic Areas
    • Female Sexual Dysfunction
    • Menopause
    • Contraception
    • Male Hypogonadism
  • Investors
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Request Information
    • Forward-Looking Statements
  • Newsroom
    • News Releases
    • Media Kit

Improving health for life

BioSante´s corporate strategy is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and its company.



LibiGel® is a transdermal testosterone gel in development for the treatment of female sexual dysfunction (FSD).

06/10/2013 – Leading Independent Proxy Advisory Firms ISS and Glass, Lewis & Co., LLC Recommend Vote “FOR” BioSante/ANI Merger 05/10/2013 – BioSante Pharmaceuticals, Inc. Reports First Quarter Financial Results 05/08/2013 – BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Special Meetings of Stockholders to Consider Proposed Merger
Copyright © BioSante Pharmaceuticals
Contact Us Site Map NASDAQ:BPAX Legal